MARK JOEL CULANAG: Open Payments
NPI 1306489331 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$969 in 27 payments from 8 companies in 2025. Trend: 2023 $147 · 2024 $327 · 2025 $969
Food & beverage: $969
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $323 |
| AstraZeneca Pharmaceuticals LP | 7 | $310 |
| Lilly USA, LLC | 3 | $163 |
| PFIZER INC. | 4 | $93 |
| Amgen Inc. | 2 | $29 |
| Dexcom, Inc. | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $17 |
| Exact Sciences Corporation | 1 | $15 |
Products named: Wegovy, BREZTRI, JARDIANCE, AIRSUPRA, NURTEC ODT, Ozempic, Repatha, FARXIGA.
Industry payments across NV — which companies pay providers there.
